Novel CGRP Monoclonal Antibodies and CGRP Receptor Antagonists: A Recipe for Success in Migraine Prevention and Treatment

Thursday, September 8, 2022

3:05 PM – 4:05 PM

Presenter(s)

Shirley Kessel, BS

Executive Director
Miles for Migraine
Phila, Pennsylvania, United States
Stephanie J. Nahas, MD, MSEd, FAHS, FAAN

Associate Professor of Neurology
Thomas Jefferson University, Jefferson Headache Center
Thomas Jefferson University, Jefferson Headache Center
Philadelphia, Pennsylvania, United States

Moderator(s)

Stephanie J. Nahas, MD, MSEd, FAHS, FAAN

Associate Professor of Neurology
Thomas Jefferson University, Jefferson Headache Center
Thomas Jefferson University, Jefferson Headache Center
Philadelphia, Pennsylvania, United States

Recent research suggests that taking calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) combined with CGRP receptor antagonists (gepants) appears to be safe and effective for migraine. Emerging evidence like this is very promising for patients who suffer from this debilitating neurological condition. This session will explore the use of novel CGRP mAbs and CGRP receptor antagonists for the management of migraine.

Supported through independent educational grants from AbbVie Inc., Biohaven Pharmaceuticals, Inc., Lundbeck, and Teva Pharmaceuticals.

Learning Objectives:

Describe the prevalence and key causes of suboptimal migraine management despite available treatment options
Evaluate the mechanisms of action, most recent efficacy and safety data, and administration considerations associated with current and emerging therapies for the treatment and prevention of migraine
Assess patient response to current therapy and integrate novel migraine therapies as appropriate into patient-centered care strategies